APP
BPMC

Avantax Planning Partners’s Blueprint Medicines BPMC Stock Holding History

Avantax Planning Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60
Closed -$5K – 400
2018
Q3 		$5K Buy
+60
New +$4.17K ﹤0.01% 1077

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Avantax Planning Partners's BPMC Position: Q4 2018 in Review

Avantax Planning Partners sold out of Blueprint Medicines (BPMC) in Q4 2018, closing a stake of 60 shares — an estimated $5K sold.

Avantax Planning Partners first reported a position in BPMC in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 162 funds tracked by Wall St. Rank hold BPMC as of Q4 2018.

  • Avantax Planning Partners reported no remaining Blueprint Medicines position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 60 Blueprint Medicines shares in Q4 2018, an estimated $5K.
  • Avantax Planning Partners first reported a position in Blueprint Medicines in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Blueprint Medicines position peaked at $5K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.